NAI Acne

Drug Profile

NAI Acne

Alternative Names: BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acne

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cassiopea; NAICONS
  • Class Amides; Antiacnes; Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Peptide elongation factor Tu inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 20 Jun 2003 Clinical data from a media release have been added to the adverse events section
  • 20 Jun 2003 Vicuron has completed a phase I trial in Acne in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top